KCNA3 and autoimmune disease: Both plasma membrane and intracellular potassium channels represent appealing pharmacological targets to treat a variety of disorders including epilepsy (Kv7.2), autoimmune diseases (Kv1.3), multiple sclerosis (Kv1), cancer (Kv1.3 and Kv11), diabetes (KATP), hypertension (KATP and ROMK), and have led to the discovery of commercially available drugs [71].